Tenax Therapeutics, Inc.2024财年第二财季实现净利润-3.58百万美元，同比减少222.52%

市场透视08-23 00:00

8月23日，Tenax Therapeutics, Inc.（TENX.US）公布财报，公告显示公司2024财年第二财季净利润为-3.58百万美元，同比减少222.52%；其中营业收入为0.00美元，每股基本收益为-1.83美元。从资产负债表来看，Tenax Therapeutics, Inc.（TENX.US）总负债1.74百万美元，其中短期债务278802.00美元，资产负债比为6.11，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2461534704?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-23 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2461534704","market":"us","top_or_hot":-1,"title":"Tenax Therapeutics, Inc.2024财年第二财季实现净利润-3.58百万美元，同比减少222.52%","media":"市场透视","content":"<div>\n<p>8月23日，Tenax Therapeutics, Inc.（TENX.US）公布财报，公告显示公司2024财年第二财季净利润为-3.58百万美元，同比减少222.52%；其中营业收入为0.00美元，每股基本收益为-1.83美元。从资产负债表来看，Tenax Therapeutics, Inc.（TENX.US）总负债1.74百万美元，其中短期债务278802.00美元，资产负债比为6.11，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082300011295b4b13d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tenax Therapeutics, Inc.2024财年第二财季实现净利润-3.58百万美元，同比减少222.52%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenax Therapeutics, Inc.2024财年第二财季实现净利润-3.58百万美元，同比减少222.52%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-23 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082300011295b4b13d&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月23日，Tenax Therapeutics, Inc.（TENX.US）公布财报，公告显示公司2024财年第二财季净利润为-3.58百万美元，同比减少222.52%；其中营业收入为0.00美元，每股基本收益为-1.83美元。从资产负债表来看，Tenax Therapeutics, Inc.（TENX.US）总负债1.74百万美元，其中短期债务278802.00美元，资产负债比为6.11，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082300011295b4b13d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082300011295b4b13d&s=b","article_id":"2461534704","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082300011295b4b13d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2461534704","pubTimestamp":1724342457,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月23日，Tenax Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-3.58百万美元，同比减少222.52%；其中营业收入为0.00美元，每股基本收益为-1.83美元。从资产负债表来看，Tenax Therapeutics, Inc.总负债1.74百万美元，其中短期债务278802.00美元，资产负债比为6.11，流动比率为6.11。机构评级：截至2024年8月23日，当前有2家机构对Tenax Therapeutics, Inc.目标价做出预测，其中目标均价为32.50美元，其中最低目标价为30.00美元，最高目标价为35.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","TENX":"Tenax Therapeutics, Inc."},"translate_title":"Tenax Therapeutics, Inc. achieved net profit of-US $3.58 million in the second fiscal quarter of fiscal 2024, a year-on-year decrease of 222.52%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"TENX":1},"content_text":"8月23日，Tenax Therapeutics, Inc.（TENX.US）公布财报，公告显示公司2024财年第二财季净利润为-3.58百万美元，同比减少222.52%；其中营业收入为0.00美元，每股基本收益为-1.83美元。从资产负债表来看，Tenax Therapeutics, Inc.（TENX.US）总负债1.74百万美元，其中短期债务278802.00美元，资产负债比为6.11，流动比率为6.11。机构评级：截至2024年8月23日，当前有2家机构对Tenax Therapeutics, Inc.目标价做出预测，其中目标均价为32.50美元，其中最低目标价为30.00美元，最高目标价为35.00美元。公司简介：Tenax Therapeutics Inc是一家专业制药公司，致力于识别、开发和商业化，解决那些盖度未满足医疗需求的心血管疾病和肺部疾病的产品。 该公司拥有左西孟旦在北美的开发和商业化权利，并发布了有关使用左西孟旦治疗与心力衰竭和保留射血分数相关的肺动脉高压的 2 期临床试验的主要数据。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461534704"}